ImmunoGen Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $15.38
- Today's High:
- $15.89
- Open Price:
- $15.66
- 52W Low:
- $3.61
- 52W High:
- $20.69
- Prev. Close:
- $15.67
- Volume:
- 2507158
Company Statistics
- Market Cap.:
- $3.90 billion
- Book Value:
- 1.974
- Revenue TTM:
- $189.56 million
- Operating Margin TTM:
- -96.84%
- Gross Profit TTM:
- $-104764000
- Profit Margin:
- -96.02%
- Return on Assets TTM:
- -20.19%
- Return on Equity TTM:
- -49.15%
Company Profile
ImmunoGen Inc had its IPO on 1989-11-16 under the ticker symbol IMGN.
The company operates in the Healthcare sector and Biotechnology industry. ImmunoGen Inc has a staff strength of 277 employees.
Stock update
Shares of ImmunoGen Inc opened at $15.66 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $15.38 - $15.89, and closed at $15.45.
This is a -1.4% slip from the previous day's closing price.
A total volume of 2,507,158 shares were traded at the close of the day’s session.
In the last one week, shares of ImmunoGen Inc have slipped by -2.95%.
ImmunoGen Inc's Key Ratios
ImmunoGen Inc has a market cap of $3.90 billion, indicating a price to book ratio of 6.4114 and a price to sales ratio of 11.4754.
In the last 12-months ImmunoGen Inc’s revenue was $189.56 million with a gross profit of $-104764000 and an EBITDA of $-181843008. The EBITDA ratio measures ImmunoGen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ImmunoGen Inc’s operating margin was -96.84% while its return on assets stood at -20.19% with a return of equity of -49.15%.
In Q2, ImmunoGen Inc’s quarterly earnings growth was a positive 407.8% while revenue growth was a positive 487.2%.
ImmunoGen Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ImmunoGen Inc’s profitability.
ImmunoGen Inc stock is trading at a EV to sales ratio of 8.8693 and a EV to EBITDA ratio of -4.3725. Its price to sales ratio in the trailing 12-months stood at 11.4754.
ImmunoGen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $714.33 million
- Total Liabilities
- $93.70 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $78000
- Dividend Payout Ratio
- 0%
ImmunoGen Inc ended 2024 with $714.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $714.33 million while shareholder equity stood at $490.84 million.
ImmunoGen Inc ended 2024 with $0 in deferred long-term liabilities, $93.70 million in other current liabilities, 2374000.00 in common stock, $-1739334000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $571.99 million and cash and short-term investments were $571.99 million. The company’s total short-term debt was $4,334,000 while long-term debt stood at $71.96 million.
ImmunoGen Inc’s total current assets stands at $571.99 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $79.96 million compared to accounts payable of $18.44 million and inventory worth $3.23 million.
In 2024, ImmunoGen Inc's operating cash flow was $0 while its capital expenditure stood at $78000.
Comparatively, ImmunoGen Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $15.45
- 52-Week High
- $20.69
- 52-Week Low
- $3.61
- Analyst Target Price
- $23.67
ImmunoGen Inc stock is currently trading at $15.45 per share. It touched a 52-week high of $20.69 and a 52-week low of $20.69. Analysts tracking the stock have a 12-month average target price of $23.67.
Its 50-day moving average was $16.95 and 200-day moving average was $9.87 The short ratio stood at 3.19 indicating a short percent outstanding of 0%.
Around 30.2% of the company’s stock are held by insiders while 8466.2% are held by institutions.
Frequently Asked Questions About ImmunoGen Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.